Journey West: How One Small Chinese Firm Is Taking On The World

Global Place For Affordable AMD Option?

When it kicked off a pivotal study in 32 countries, a small Chengdu-based company stepped into unknown waters littered with challenges, ranging from lack of expertise to limited enthusiasm for a made in China new drug, from controls over foreign currency outflows to vetting investigators in foreign lands. But a strong early performance at home has given Kanghong confidence to take on big pharma and the world.

KANGHONG VP SHU CHEN TALKS ABOUT THE CONBERCEPT GLOBAL PIII STUDY
KANGHONG VP SHU CHEN DISCUSSES CONBERCEPT GLOBAL STUDY AT CPhI China On 16 DEC 2020 • Source: Brian Yang

More from China

More from Focus On Asia